TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2342006

Group type: EXPERIMENTAL
Intervention: Cefotetan (2 g intravenously with induction of anaesthesia)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Piperacillin (three doses of 2 g)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Cefotetan
Number of subjects: 153

Group type: COMPARATOR
Intervention: Piperacillin
Number of subjects: 153
Study: 6242956

Group type: EXPERIMENTAL
Intervention: Piroxicam 20 mg mane
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Piroxicam 20 mg nocte
Number of subjects: 33
Study: 31947205

Group type: EXPERIMENTAL
Intervention: Visual group (using a radius‐varying sphere)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Auditory group (using a volume‐varying sound)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 16
Study: 28169932

Group type: EXPERIMENTAL
Intervention: Simulation-based ultrasound training and clinical training
Number of subjects: 54

Group type: COMPARATOR
Intervention: Clinical training only
Number of subjects: 54
Study: 25444961

Group type: EXPERIMENTAL
Intervention: Group urotherapy (1-hour session)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Individual urotherapy (15-minute session)
Number of subjects: 60
Study: 23803049

Group type: EXPERIMENTAL
Intervention: Intervention group received a tobacco cessation booklet and four sessions of counselling including a group counselling cum medical camp, followed by proactive counselling through face-to-face (FTF) interview and mobile phone.
Number of subjects: 928

Group type: EXPERIMENTAL
Intervention: Individual counselling in the second session (4-6 weeks time period).
Number of subjects: 928

Group type: EXPERIMENTAL
Intervention: Follow-up at 3 months.
Number of subjects: 928

Group type: EXPERIMENTAL
Intervention: Follow-up at 6 months (fourth session).
Number of subjects: 928

Group type: EXPERIMENTAL
Intervention: Overall contact rate in the intervention group.
Number of subjects: 928
Study: 21342737

Group type: EXPERIMENTAL
Intervention: Multidisciplinary nutritional care during hospitalization and transfer of nutritional care after discharge
Number of subjects: 127

Group type: COMPARATOR
Intervention: Standard nutritional care
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Multidisciplinary nutritional care
Number of subjects: 127
Study: 19355844

Group type: EXPERIMENTAL
Intervention: Cholinesterase inhibitor (ChEI) treatment for 20 weeks
Number of subjects: 26

Group type: COMPARATOR
Intervention: Healthy elderly age-matched controls
Number of subjects: 26
Study: 17766527

Group type: EXPERIMENTAL
Intervention: Early enteral iron supplementation
Number of subjects: 164

Group type: COMPARATOR
Intervention: Late enteral iron supplementation
Number of subjects: 164
Study: 14739496

Group type: EXPERIMENTAL
Intervention: roxithromycin (ROM) 2x150 mg/day orally for 4 weeks
Number of subjects: 46

Group type: COMPARATOR
Intervention: placebo 2x1 tablet/day for 4 weeks
Number of subjects: 46
Study: 11552198

Group type: EXPERIMENTAL
Intervention: Supervised stretching of the rectus femoris muscle (4 times/week for 2 weeks)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Calf muscles stretching (control treatment)
Number of subjects: 29
Study: 9972406

Group type: EXPERIMENTAL
Intervention: Liposomal encapsulated doxorubicin (DOX‐SL) 20‐40mg/m2 administered by intravenous infusion over 30‐60 minutes every two weeks
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Liposomal encapsulated doxorubicin (DOX‐SL)
Number of subjects: 25
Study: 8147492

Group type: EXPERIMENTAL
Intervention: Ivermectin 20 micrograms/kg
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Ivermectin 100 micrograms/kg
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Ivermectin 200 micrograms/kg
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Ivermectin (all dosages)
Number of subjects: 43
Study: 3130890

Group type: EXPERIMENTAL
Intervention: Atropine 1 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Mequitazine 5 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Terfenadine 60 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31018832

Group type: EXPERIMENTAL
Intervention: Mifamurtide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Historical individual control data
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aggregate treatment effect estimates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Piecewise exponential model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weibull model
Number of subjects: 0
Study: 26914485

Group type: EXPERIMENTAL
Intervention: NIR-assisted procedure
Number of subjects: 103

Group type: COMPARATOR
Intervention: Standard venipuncture
Number of subjects: 103
Study: 26239735

Group type: EXPERIMENTAL
Intervention: Deferiprone and silymarin for 9 months
Number of subjects: 80

Group type: COMPARATOR
Intervention: Deferiprone and placebo for 9 months
Number of subjects: 80
Study: 22709363

Group type: EXPERIMENTAL
Intervention: 30-min nurse-led computerized Predict CVD-Diabetes session
Number of subjects: 106

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 106
Study: 20390429

Group type: EXPERIMENTAL
Intervention: Zibotentan (ZD4054) 10 mg or 15 mg
Number of subjects: 312

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 312
Study: 18579392

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 67
Study: 16352882

Group type: EXPERIMENTAL
Intervention: Composite resin sealants
Number of subjects: 103

Group type: COMPARATOR
Intervention: Glass ionomer sealants
Number of subjects: 103
Study: 12827121

Group type: EXPERIMENTAL
Intervention: Topical local anesthetic (adrenaline 1:1,000, lignocaine 4%, amethocaine 0.5%)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo (adrenaline 1:1,000 solution)
Number of subjects: 161
Study: 10819253

Group type: EXPERIMENTAL
Intervention: Shunts with low working pressure
Number of subjects: 101

Group type: COMPARATOR
Intervention: Shunts with medium-high working pressure
Number of subjects: 101
Study: 8894262

Group type: EXPERIMENTAL
Intervention: Quinapril (10 mg, doubled to 40 mg in nonresponders)
Number of subjects: 5609

Group type: COMPARATOR
Intervention: Metoprolol (50 mg, doubled to 200 mg in nonresponders)
Number of subjects: 5609

Group type: EXPERIMENTAL
Intervention: Quinapril (52 weeks treatment in a volunteer group of 327 patients)
Number of subjects: 5609

Group type: COMPARATOR
Intervention: Metoprolol (52 weeks treatment in a volunteer group of 327 patients)
Number of subjects: 5609
Study: 1686701

Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (conventional postoperative methods)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Protocol group (simulated outpatient protocol)
Number of subjects: 40
Study: 6144696

Group type: EXPERIMENTAL
Intervention: Semantic desensitization
Number of subjects: 30

Group type: COMPARATOR
Intervention: Attention placebo
Number of subjects: 30

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 30
Study: 30616662

Group type: EXPERIMENTAL
Intervention: MATCH (Modular Approach to Therapy for children with Anxiety, Depression, Trauma and Conduct problems)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 280
Study: 29237489

Group type: EXPERIMENTAL
Intervention: High chronic outward force (COF) group (LifeStent Flexstar, Bard Peripheral Vascular Inc.)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Low chronic outward force (COF) group (Pulsar, Biotronik AG)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: High COF group
Number of subjects: 80

Group type: COMPARATOR
Intervention: Low COF group
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study: 25540062

Group type: EXPERIMENTAL
Intervention: Racing game
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral game
Number of subjects: 0
Study: 24838401

Group type: EXPERIMENTAL
Intervention: Listening to music during electromyography
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no music)
Number of subjects: 60
Study: 22967497

Group type: EXPERIMENTAL
Intervention: Antazoline administered intravenously in divided doses
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo administered intravenously in divided doses
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Antazoline
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 19631852

Group type: EXPERIMENTAL
Intervention: Indirect pulp capping treatment; specific details on dosage and duration not available.
Number of subjects: 0
Study: 17469162

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CYC)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study: 15787181

Group type: EXPERIMENTAL
Intervention: Catalin eye drops
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 11252048

Group type: EXPERIMENTAL
Intervention: Cost-minimization analysis (CMA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis (CEA)
Number of subjects: 0
Study: 9581139

Group type: EXPERIMENTAL
Intervention: Critical pathway protocol
Number of subjects: 149

Group type: COMPARATOR
Intervention: Conventional means
Number of subjects: 149
Study: 8277200

Group type: EXPERIMENTAL
Intervention: Inactivated vaccine
Number of subjects: 5210

Group type: EXPERIMENTAL
Intervention: Cold-adapted vaccine
Number of subjects: 5210
Study: 2470865

Group type: EXPERIMENTAL
Intervention: DDP-BLM
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: VBM
Number of subjects: 45
Study: 1094034

Group type: EXPERIMENTAL
Intervention: Benzethonium chloride mouthrinse
Number of subjects: 43

Group type: COMPARATOR
Intervention: Zinc chloride mouthrinse
Number of subjects: 43

Group type: COMPARATOR
Intervention: Benzethonium chloride combined with zinc chloride mouthrinse
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo mouthrinse
Number of subjects: 43
Study: 31585174

Group type: EXPERIMENTAL
Intervention: Factorial design trials
Number of subjects: 100
Study: 30543761

Group type: EXPERIMENTAL
Intervention: Interactive, educational advance care planning (ACP) decision aid
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard advance care planning (ACP)
Number of subjects: 200
Study: 28781129

Group type: EXPERIMENTAL
Intervention: IH oxytocin 400μg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: IH oxytocin (all doses)
Number of subjects: 16

Group type: COMPARATOR
Intervention: IH placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: IH oxytocin
Number of subjects: 16
Study: 26011569

Group type: EXPERIMENTAL
Intervention: S-Adenosyl Methionine (SAMe)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 189

Group type: COMPARATOR
Intervention: Escitalopram (selective serotonin reuptake inhibitor)
Number of subjects: 189
Study: 23154592

Group type: EXPERIMENTAL
Intervention: Customized, guideline-oriented training program for hypertension management
Number of subjects: 140

Group type: COMPARATOR
Intervention: Usual care provided by primary healthcare providers in control centers
Number of subjects: 140
Study: 20738455

Group type: EXPERIMENTAL
Intervention: Smoking cessation support
Number of subjects: 6
Study: 18053020

Group type: EXPERIMENTAL
Intervention: Triflusal (225 mg, 450 mg, 900 mg)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 17067505

Group type: EXPERIMENTAL
Intervention: Substances or factors that stimulate or inhibit the reabsorption process of pulmonary edema
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transpulmonary thermodilution
Number of subjects: 0
Study: 12671885

Group type: EXPERIMENTAL
Intervention: Fructooligosaccharides (FOS) 6.6 g, administered 3 times daily after meals
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 10626715

Group type: EXPERIMENTAL
Intervention: 0.167 microg x kg(‐1) x hr(‐1) of naloxone (Group 4)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 0.125 microg x kg(‐1) x hr(‐1) of naloxone (Group 3)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 0.083 microg x kg(‐1) x hr(‐1) of naloxone (Group 2)
Number of subjects: 80

Group type: COMPARATOR
Intervention: 2 mg epidural morphine bolus with continuous epidural infusion of 4 mg morphine in 100 ml bupivacaine 0.125% (Group 1)
Number of subjects: 80
Study: 9174679

Group type: EXPERIMENTAL
Intervention: Ibuprofen effervescent 400 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ibuprofen effervescent 800 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Ibuprofen tablets 400 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Ibuprofen tablets 800 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ibuprofen effervescent
Number of subjects: 20
Study: 8254241

Group type: EXPERIMENTAL
Intervention: Immediate carotid endarterectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-surgery
Number of subjects: 0
Study: 3818160

Group type: EXPERIMENTAL
Intervention: Increased smoking involvement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Decreased smoking involvement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Discriminant function models
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Variables measured in 1975
Number of subjects: 0
Study: 29347904

Group type: EXPERIMENTAL
Intervention: Social skills training
Number of subjects: 91

Group type: COMPARATOR
Intervention: Resource activating play group
Number of subjects: 91
Study: 30345030

Group type: EXPERIMENTAL
Intervention: Sonographers reporting high visualization rates (>89%) of normal postmenopausal ovaries
Number of subjects: 349

Group type: COMPARATOR
Intervention: Expert review of examinations
Number of subjects: 349
Study: 26575861

Group type: EXPERIMENTAL
Intervention: Seated pedaling at varying crank powers (20% to 120%)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Standing pedaling at varying crank powers (20% to 120%)
Number of subjects: 17
Study: 23682858

Group type: EXPERIMENTAL
Intervention: Exercise group (60-min exercise class twice a week for 3 months)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Education group (control)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Excluded subjects (control)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Exercise group
Number of subjects: 105

Group type: COMPARATOR
Intervention: Excluded participants
Number of subjects: 105
Study: 23050472

Group type: EXPERIMENTAL
Intervention: FB1 alone (FX)
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: M alone (MX)
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: FB1 and M (FM)
Number of subjects: 390

Group type: COMPARATOR
Intervention: Chick mash alone (CX)
Number of subjects: 390
Study: 19594035

Group type: EXPERIMENTAL
Intervention: Comprehensive rehabilitation therapy including joint range of motion, activities of daily living, and restoring muscle strength starting from the 2nd day after surgery.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Not applicable (control group did not receive rehabilitation).
Number of subjects: 100
Study: 17877855

Group type: EXPERIMENTAL
Intervention: Mortality salience (MS) with reminders of human creatureliness
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thoughts about human creatureliness
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 15667657

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Quetiapine (subgroup with co-morbid tics)
Number of subjects: 42
Study: 11994702

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 9661542

Group type: EXPERIMENTAL
Intervention: Warming intravenous fluids at 42 degrees C
Number of subjects: 38

Group type: COMPARATOR
Intervention: Room temperature fluids at approximately 21 degrees C (Control)
Number of subjects: 38
Study: 7854554

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy according to IOR‐OS/NEO 3 protocol
Number of subjects: 55
Study: 2574496

Group type: EXPERIMENTAL
Intervention: Timolol (non-selective beta blocker)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Atenolol (beta-1 selective beta blocker)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 6
Study: 237423

Group type: EXPERIMENTAL
Intervention: AH 8165 D (0.4-0.8 mg/kg body weight)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: AH 8165 D
Number of subjects: 50
Study: 31574127

Group type: EXPERIMENTAL
Intervention: Psycho-social support by trained school teachers
Number of subjects: 1220

Group type: COMPARATOR
Intervention: Control group (no psycho-social support)
Number of subjects: 1220
Study: 27302563

Group type: EXPERIMENTAL
Intervention: HMB supplementation
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 25819854

Group type: EXPERIMENTAL
Intervention: Lutonix drug-coated balloon (DCB)
Number of subjects: 476

Group type: COMPARATOR
Intervention: Percutaneous transluminal angioplasty (PTA)
Number of subjects: 476
Study: 23627460

Group type: EXPERIMENTAL
Intervention: Recombinant human IL-10 (rhIL-10) at various concentrations in rats
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Recombinant human IL-10 (rhIL-10) at low concentrations in humans
Number of subjects: 175

Group type: COMPARATOR
Intervention: Double deletion of IL-10 and IL-4 genes in KO mice
Number of subjects: 175

Group type: COMPARATOR
Intervention: Control incisions receiving either placebo or standard care in rats
Number of subjects: 175

Group type: COMPARATOR
Intervention: Control incisions receiving either standard care or placebo in humans
Number of subjects: 175
Study: 21932567

Group type: EXPERIMENTAL
Intervention: Beta-blocker metoprolol tartrate
Number of subjects: 45

Group type: COMPARATOR
Intervention: Standard antianginal therapy (including nitrates, anticoagulants, ACE inhibitors, and statins)
Number of subjects: 45
Study: 19304668

Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation (3-month training)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Non-training group
Number of subjects: 39
Study: 16169185

Group type: EXPERIMENTAL
Intervention: Intensive cognitive-behavioral group treatment (CBGT)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Waiting list control group (WG)
Number of subjects: 26
Study: 15208485

Group type: EXPERIMENTAL
Intervention: Rhythm control
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rate control
Number of subjects: 0
Study: 11738278

Group type: EXPERIMENTAL
Intervention: Pravastatin for six months followed by pravastatin and vitamin E for six additional months
Number of subjects: 54

Group type: COMPARATOR
Intervention: Vitamin E for six months followed by pravastatin and vitamin E for six additional months
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Simvastatin for six months followed by simvastatin and vitamins C and E for six additional months
Number of subjects: 54
Study: 10481384

Group type: EXPERIMENTAL
Intervention: Flow cytometry (FC)
Number of subjects: 131
Study: 8110914

Group type: EXPERIMENTAL
Intervention: Lithium treatment (mean serum level of 0.54 mEq/L)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lithium treatment and Placebo treatment
Number of subjects: 30
Study: 3606937

Group type: EXPERIMENTAL
Intervention: Dextropropoxyphene hydrochloride 65 mg 8 hourly
Number of subjects: 12

Group type: COMPARATOR
Intervention: Theophylline 125 mg 8 hourly
Number of subjects: 12

Group type: COMPARATOR
Intervention: Tolbutamide 500 mg i.v.
Number of subjects: 12
Study: 29866131

Group type: EXPERIMENTAL
Intervention: Spinal manipulative therapy (SMT) with co-intervention exercise strategies (spine mobilizing and multifidus activating)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Spinal manipulative therapy (SMT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No additional treatment
Number of subjects: 0
Study: 27831729

Group type: EXPERIMENTAL
Intervention: Problem solving and communication (CAPS) group
Number of subjects: 132

Group type: COMPARATOR
Intervention: Internet resources comparison (IRC) group
Number of subjects: 132
Study: 23473623

Group type: EXPERIMENTAL
Intervention: Aerobic capacity (VO2 peak)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Antihypertensive medication use
Number of subjects: 35
Study: 23591985

Group type: EXPERIMENTAL
Intervention: Exercising + XS
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Exercising + STD
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control + STD
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control + XS
Number of subjects: 26
Study: 20015106

Group type: EXPERIMENTAL
Intervention: Mobile Crisis Team (MCT) intervention
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard referral to outpatient mental health clinic (OPC)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both MCT and OPC
Number of subjects: 120
Study: 19014835

Group type: EXPERIMENTAL
Intervention: Bevirimat 200 mg/d for 14 days
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Atazanavir 400 mg/d on days 1 through 21 and bevirimat 200 mg/d on days 8 through 21
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Coadministration of bevirimat and atazanavir
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Treatment-emergent adverse events
Number of subjects: 48

Group type: COMPARATOR
Intervention: Atazanavir monotherapy
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Bevirimat + atazanavir
Number of subjects: 48